Artificial Intelligence Risk Model Validated for Predicting Breast Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 4, 2024 -- Across European populations, an artificial intelligence (AI) risk model shows generalizable discriminatory performance for predicting breast cancer among women with a negative mammogram, according to a study published online Dec. 6 in The Lancet Regional Health: Europe.
Mikael Eriksson, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues used four European screening populations in three countries screened between 2009 and 2020 for women aged 45 to 69 years to assess the predictive performance of an AI-based risk model. Data were included for 739 women with incident breast cancers and 7,812 controls. Mammographic features were extracted using AI from negative digital mammograms. The two-year absolute risks for breast cancer were predicted and examined after two-year follow-up.
The researchers found that for breast cancers developed in four screening populations, the overall adjusted area under the receiver operating characteristic curve of the AI risk model was 0.72. Cancers were more likely diagnosed after two years of follow-up in the 6.2 percent of women at high risk using the National Institute of Health and Care Excellence guideline thresholds compared with the 69 percent of women classified as general risk by the model (risk ratio, 6.7). Across levels of mammographic density, similar risk ratios were observed.
"An image-derived AI model is feasible for personalized breast cancer screening to improve the screening outcomes," the authors write.
One author has a patent on a system and method for assessing breast cancer risk using imagery with a license to iCAD.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Pembrolizumab + Chemo Beneficial for Early-Stage Triple-Negative Breast Cancer
THURSDAY, Sept. 19, 2024 -- For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a...
DBT Increases Cancer Detection Versus Digital Mammography
THURSDAY, Sept. 19, 2024 -- Digital breast tomosynthesis (DBT) can increase cancer detection compared with two-dimensional digital mammography (DM), according to a study published...
Live Birth Rate Similar With Blastocyst, Cleavage Stage Embryo Transfer
THURSDAY, Sept. 19, 2024 -- For women with at least four embryos available during in vitro fertilization (IVF) treatment, blastocyst embryo transfers result in a similar...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.